Tolerability, Safety and Pharmacokinetics in Healthy Subjects of Single Intravenous Doses of Debio 1450 (Previously AFN-1720), a Prodrug of the Staphylococcocal-specific Antibiotic Debio 1452 (Previously AFN-1252)

B. Hafkin (1;3), N. Kaplan (2;3)

Presented at ECCMID 2014, Barcelona, Spain

(1) Affinium Pharmaceuticals, Austin, TX, USA

(2) Affinium Pharmaceuticals, Toronto, ON, Canada

(3) Debiopharm International SA, Lausanne, Switzerland